Drug Profile
Research programme: finafloxacin/hsp70 inhibitor - Chaperone/MerLion
Alternative Names: Finafloxacin/hsp70 inhibitor - Chaperone/MerLionLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Chaperone Technologies; MerLion Pharmaceuticals
- Class Fluoroquinolones; Small molecules
- Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors; HSP70 heat shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Bacterial-infections in USA
- 04 Dec 2009 Early research in Bacterial infections in USA (unspecified route)